

**Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856)**  
**Recombinant Antibody**  
**Catalog # APR11074****Specification**

---

**Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | FC, E, FTA             |
| Primary Accession | <a href="#">P35916</a> |
| Reactivity        | Human                  |
| Clonality         | Monoclonal             |
| Isotype           | IgG1                   |
| Calculated MW     | 146.18 KDa             |

**Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) - Additional Information****Target/Specificity**  
VEGFR3 / FLT4**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) - Protein Information****Name** FLT4**Synonyms** VEGFR3**Function**

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a

truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

#### Cellular Location

Cell membrane; Single-pass type I membrane protein Cytoplasm Nucleus. Note=Ligand-mediated autophosphorylation leads to rapid internalization [Isoform 2]: Cell membrane; Single-pass type I membrane protein

#### Tissue Location


Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney.

### Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) - Images



Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) is more than 98.74% ,determined by SEC-HPLC.